Drug intelligence / Profile preview

UHAC 62 XX - TF1

Development stage: Unknown
Lead developer: Boehringer Ingelheim
Modality: Small Molecules
Administration: Oral

Overview

UHAC 62 XX - TF1 is a tablet formulation of meloxicam, a non-steroidal anti-inflammatory drug (NSAID). It was developed as an alternative to the capsule formulation of meloxicam (UHAC 62 XX) and was tested in bioequivalence studies to compare its pharmacokinetic properties with the capsule formulation.

Targets

PGHS-1 (Prostaglandin G/H Synthase 1)

Beyond the preview

Go deeper on UHAC 62 XX - TF1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on UHAC 62 XX - TF1.

Explore the full profile